A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease

Penelope G. Foulds; Peter Diggle; J. Douglas Mitchell; Angela Parker; Masato Hasegawa; Masami Masuda-Suzukake; David M.A. Mann; David Allsop

doi:10.1038/srep02540

A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease

Penelope G. Foulds
, Peter Diggle
, J. Douglas Mitchell
, Angela Parker
, Masato Hasegawa
, Masami Masuda-Suzukake
, David M.A. Mann
, David Allsop

Research output: Contribution to journal › Article › peer-review

156 Citations (Scopus)

Abstract

There have been no longitudinal studies on a-synuclein as a potential biomarker for the progression of Parkinson's disease (PD). Here, blood plasma 'total a-synuclein' and 'Ser-129 phosphorylated α-synuclein' were assayed at 4-6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total a-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p 5 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated a-synuclein, but not of total a-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p50.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total a-synuclein could act as a surrogate marker for the progression of PD.

Original language	English
Article number	2540
Journal	Scientific Reports
Volume	3
DOIs	https://doi.org/10.1038/srep02540
Publication status	Published - 29 Aug 2013
Externally published	Yes

Access to Document

10.1038/srep02540Licence: CC BY

Cite this

@article{4bee70d0729a4c05a2d2c4461a1f1eae,

title = "A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease",

abstract = "There have been no longitudinal studies on a-synuclein as a potential biomarker for the progression of Parkinson's disease (PD). Here, blood plasma 'total a-synuclein' and 'Ser-129 phosphorylated α-synuclein' were assayed at 4-6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total a-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p 5 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated a-synuclein, but not of total a-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p50.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total a-synuclein could act as a surrogate marker for the progression of PD.",

author = "Foulds, \{Penelope G.\} and Peter Diggle and Mitchell, \{J. Douglas\} and Angela Parker and Masato Hasegawa and Masami Masuda-Suzukake and Mann, \{David M.A.\} and David Allsop",

year = "2013",

month = aug,

day = "29",

doi = "10.1038/srep02540",

language = "English",

volume = "3",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease

AU - Foulds, Penelope G.

AU - Diggle, Peter

AU - Mitchell, J. Douglas

AU - Parker, Angela

AU - Hasegawa, Masato

AU - Masuda-Suzukake, Masami

AU - Mann, David M.A.

AU - Allsop, David

PY - 2013/8/29

Y1 - 2013/8/29

N2 - There have been no longitudinal studies on a-synuclein as a potential biomarker for the progression of Parkinson's disease (PD). Here, blood plasma 'total a-synuclein' and 'Ser-129 phosphorylated α-synuclein' were assayed at 4-6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total a-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p 5 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated a-synuclein, but not of total a-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p50.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total a-synuclein could act as a surrogate marker for the progression of PD.

AB - There have been no longitudinal studies on a-synuclein as a potential biomarker for the progression of Parkinson's disease (PD). Here, blood plasma 'total a-synuclein' and 'Ser-129 phosphorylated α-synuclein' were assayed at 4-6 monthly intervals from a cohort of 189 newly-diagnosed patients with PD. For log-transformed data, plasma total a-synuclein levels increased with time for up to 20 yrs after the appearance of initial symptoms (p 5 0.012), whereas phosphorylated α-synuclein remained constant over this same period. The mean level of phosphorylated a-synuclein, but not of total a-synuclein, was higher in the PD plasma samples taken at first visit than in single samples taken from a group of 91 healthy controls (p50.012). Overall, we conclude that the plasma level of phosphorylated α-synuclein has potential value as a diagnostic tool, whereas the level of total a-synuclein could act as a surrogate marker for the progression of PD.

U2 - 10.1038/srep02540

DO - 10.1038/srep02540

M3 - Article

SN - 2045-2322

VL - 3

JO - Scientific Reports

JF - Scientific Reports

M1 - 2540

ER -

A longitudinal study on a-synuclein in blood plasma as a biomarker for Parkinson's disease

Abstract

Access to Document

Fingerprint

Cite this